Mera Tilley, PhD

Senior Director, Genomics Discovery

Mera is a translational science expert at Foresite Capital. She leverages human biology to guide research and development of novel therapeutics.

A genetic epidemiologist and human geneticist, Mera previously did a stint in the start-up world leading the Precision Medicine and Translational Genetics group at Goldfinch Bio. Prior to Goldfinch, she spent six years at Pfizer in roles across drug discovery, development, and medical affairsPrior to Pfizer, she was at the National Human Genome Research Institute, where she developed new methods for analyzing rare variants in DNA sequence data to discover novel genetic causes of coronary artery disease. During her early career she trained in a variety of fields, including molecular biology, bioinformatics, and science policy.


  • PhD from National Institutes of Health/NHGRI Intramural Graduate Partnership Program with Penn State University with science policy training in the U.S. State Department Office of the Science Advisor to Sec. Hillary Clinton
  • 8 years of pharmaceutical and biotech experience across Pfizer, Goldfinch Bio, Salimetrics and P&G.
  • Extensive experience leading precision medicine and translational genetic strategies in cardiometabolic disease, inflammation/immunology, and rare disease from early target discovery in R&D through post-marketing studies in Medical Affairs.